Ricardo E Blanco - Genetic Mutations

Author Information

Ricardo Blanco is a distinguished researcher affiliated with the Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. His work primarily focuses on the intersection of rheumatology, genetics, and atherosclerosis in systemic inflammatory diseases.

Research Contributions

Ricardo Blanco has made significant contributions to the field of rheumatology, particularly in understanding and treating autoimmune diseases. In 2022 alone, he has authored multiple impactful papers on topics ranging from the cardioprotective effects of antimalarials in lupus patients to the utility of tocilizumab in autoimmune eye diseases. His research extends to the study of biologic therapy in refractory Neurobehçet's disease and the potential use of angiogenic T cells as biomarkers for early diagnosis of interstitial lung disease in autoimmune conditions. Blanco’s extensive work also includes systematic reviews on the efficacy and safety of treatments for rheumatoid arthritis and the role of endothelial progenitor cells in systemic sclerosis-associated lung fibrosis.

Aliases

The author is known by several aliases, including R Blanco, R. Blanco, Ricardo Blanco, and Ricardo E Blanco. These variations are commonly found in different publications and citation records.

Publication and Citation Metrics

Metric	Value
Citation Count	12,253
H-index	58
Paper Count	635

Publications:

Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

DOI: 10.1016/j.semarthrit.2021.11.012

Year: 2022

Advances in the Treatment of Giant Cell Arteritis

DOI: 10.3390/jcm11061588

Year: 2022

Utility of tocilizumab in autoimmune eye diseases.

DOI: 10.1080/14712598.2022.2066971

Year: 2022

Biologic therapy in refractory Neurobehçet's disease: a multicenter study of 41 patients and literature review.

DOI: 10.1093/rheumatology/keac097

Year: 2022

Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?

DOI: 10.3390/biomedicines10040851

Year: 2022

Correction: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics 2021, 11, 2363

DOI: 10.3390/diagnostics12020521

Year: 2022

Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.

DOI: 10.55563/clinexprheumatol/8mku9c

Year: 2022

Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.

DOI: 10.55563/clinexprheumatol/9ipkcs

Year: 2021

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

DOI: 10.1016/j.autrev.2021.102830

Year: 2021

Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients

DOI: 10.3390/biomedicines9070847

Year: 2021

What Are the Benefits of Pharmacogenomics?

What is the Mechanism of Action of TKIs?

Can Genetic Mutations Be Inherited?

Why are Improved Diagnostic Tools Important?

What is Brain Development?

What Are the Common PARP Inhibitors?

What are the Challenges Ahead?

What is Cellular Heterogeneity?

How do Duplications Occur?

Why Does Sickle Cell Trait Persist in the Population?

Partnered Content Networks

Relevant Topics